98%
921
2 minutes
20
Objective: This systematic review and meta-analysis evaluates the efficacy of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in improving gastric motility in patients with Parkinson's disease (PD).
Materials And Methods: A systematic search was conducted in Scopus, Web of Science, PubMed, and Cochrane CENTRAL until December 15, 2024. Observational studies and clinical trials evaluating DBS effects on gastric motility and gastric emptying in patients with PD were included. Primary outcomes were changes in the gastrointestinal (GI) domain of the Non-Motor Symptoms Scale (NMSS) and CO excretion time (T). Meta-analysis was performed using Review Manager 5.4, using a random-effects model when necessary.
Results: Eight studies (N = 379) were included. Meta-analysis showed a significant reduction in NMSS-GI domain scores after DBS (MD: -1.29, 95% CI: [-2.16, -0.42], p = 0.004). Subgroup analysis revealed sustained improvements at six months (MD: -1.46, 95% CI: [-2.34, -0.57], p = 0.001) and 12 months (mean difference [MD]: -1.12, 95% CI: [-2.23, -0.01], p = 0.05). For gastric emptying (TCO), no significant difference was found between patients on medication before DBS (with medication [WM]) and those off medication before DBS (without medication [WOM]) (MD: 2.58, 95% CI: [-3.94, 9.10], p = 0.44). However, a significant reduction in TCO was observed in DBS-ON-WOM vs DBS-OFF-WOM (MD: -11.71, 95% CI: [-17.41, -6.02], p < 0.0001) and DBS-ON-WOM vs WM before DBS (MD: -15.46, 95% CI: [-20.89, -10.03], p < 0.00001).
Conclusions: Meta-analysis suggests that STN-DBS significantly relieves GI symptoms and improves gastric motility in patients with PD, with sustained benefits over 12 months. Future studies should assess long-term effects and optimize stimulation parameters for autonomic dysfunction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neurom.2025.07.005 | DOI Listing |
Background: This systematic review and meta-analysis compared the intraoperative and postoperative outcomes of minimally invasive versus open distal pancreatectomy (ODP) in patients with pancreatic ductal adenocarcinoma (PDAC), which is a highly aggressive tumor with a high mortality rate. Surgical resection remains the only potentially curative treatment. Minimally invasive distal pancreatectomy (MIDP), including laparoscopic and robotic approaches, has gained popularity, although the evidence of its efficacy is limited.
View Article and Find Full Text PDFNeuromodulation
September 2025
Department of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA. Electronic address:
Objective: This systematic review and meta-analysis evaluates the efficacy of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in improving gastric motility in patients with Parkinson's disease (PD).
Materials And Methods: A systematic search was conducted in Scopus, Web of Science, PubMed, and Cochrane CENTRAL until December 15, 2024. Observational studies and clinical trials evaluating DBS effects on gastric motility and gastric emptying in patients with PD were included.
Int J Mol Med
November 2025
School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China.
Enterochromaffin (EC) cell dysfunction decreases 5‑hydroxytryptamine (5‑HT) secretion, contributing to functional constipation (FC). However, the underlying mechanisms remain unclear. Piezo ion channels mediate 5‑HT release from EC cells.
View Article and Find Full Text PDFBackground/ Aim: Total pancreatectomy (TP) is an uncommon type of pancreatic resection, even at high-volume centers. The indications of a TP are not fully defined, and the outcomes are controversial. The study aims to assess the frequency of use, indications, and early outcomes of TP in a contemporary consecutive series of 36 patients.
View Article and Find Full Text PDFJ Pharm Pract
September 2025
Pharmacy Practice and Translational Research Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have experienced rapid growth in recent years as treatments for type 2 diabetes mellitus and obesity. These medications offer promising benefits, including weight loss and improved glycemic control; however, their implications for reproductive health warrant attention. While tirzepatide has been shown to impact absorption of oral contraceptives due to delayed gastric emptying, other GLP-1RAs do not appear to have clinically significant interactions with oral contraception.
View Article and Find Full Text PDF